The United States has intervened in a whistleblower suit filed in the District of Massachusetts against Boehringer Ingelheim Roxane, Inc. and various related entities, alleging that Roxane violated the False Claims Act. The company is alleged to have engaged in a scheme to report false and inflated prices for several drugs. The reported prices are used to establish reimbursement rates for federal health care programs. In some instances, according to the complaint, the reported prices were more than 1,000 percent the actual sales prices on certain of the drugs. it manufactures.
The United States Attorney’s Office for the District of Massachusetts reported on the intervention in a January 29, 2007 press release.